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Abstract COPD is the third leading cause of death in the
world and its global burden is predicted to increase further.
Even though the prevalence of COPD is well studied, only
few studies examined the incidence of COPD in a prospec-
tive and standardized manner. In a prospective population-
based cohort study (Rotterdam Study) enrolling subjects
aged C45, COPD was diagnosed based on a pre-bron-
chodilator obstructive spirometry (FEV1/FVC\ 0.70). In
absence of an interpretable spirometry within the Rotterdam
Study, cases were defined as having COPD diagnosed by a
physician on the basis of clinical presentation and obstruc-
tive lung function measured by the general practitioner or
respiratory physician. Incidence rates were calculated by
dividing the number of incident cases by the total number of
person years of subjects at risk. In this cohort of 14,619
participants, 1993 subjects with COPD were identified of
whom 689 as prevalent ones and 1304 cases as incident ones.
The overall incidence rate (IR) of COPD was 8.9/1000 per-
son-years (PY); 95 % Confidence Interval (CI) 8.4–9.4. The
IR was higher in males and in smokers. The proportion of
female COPD participants without a history of smoking was
27.2 %, while this proportion was 7.3 % in males. The
prevalence of COPD in the RotterdamStudy is 4.7 % and the
overall incidence is approximately 9/1000 PY, with a higher
incidence in males and in smokers. The proportion of never-
smokers among female COPD cases is substantial.
Keywords COPD  GOLD  LLN  Prevalence 
Incidence  The Rotterdam Study
Introduction
Worldwide, Chronic Obstructive Pulmonary Disease
(COPD) is the third leading cause of death [1]. COPD is
characterized by persistent airflow limitation that is typi-
cally progressive and associated with an enhanced chronic
inflammatory response in the airways and lung tissue to
harmful particles or gases [2]. The chronic airflow limita-
tion in COPD is caused by the combination of parenchymal
destruction (emphysema) and small airways disease (ob-
structive bronchiolitis), of which the relative presence
varies from person to person [2].
According to estimates from the Global Burden of
Disease Study, COPD was prevalent in more than 300
million people in 2013 [3]. The disease burden and its
financial impact is predicted to increase, mainly due to
population aging [4–6]. Several studies reported on the
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prevalence of COPD. In European adult populations over
40 years, the prevalence of COPD ranges between
15–20 % and is higher in men than in women [7–9]. Even
though the prevalence of COPD is well known, only few
studies examined its incidence rate in a prospective and
standardized manner (supplementary Table 1S in the
Online Resource provides an overview of studies which
investigated the incidence of COPD).
While tobacco smoking is a major risk factor for COPD,
only approximately 20 % of smokers develop the disease.
More evidence is rising to suggest that other risk factors such
as air pollution, respiratory infections, poor nutritional sta-
tus, chronic asthma, impaired lung growth, poor socio-eco-
nomic status and genetic factors are also important for
disease development [10–12]. About 15–20 % of COPD
cases are due to occupational exposures to pollutants at the
workplace [9], and about 50 % of subjects who died from
COPD in developing countries have been exposed to bio-
mass smoke during lifetime [10]. These facts emphasize the
need for action in order to reduce the impact of those risk
factors on disease development. To this end, investigating
the incidence of COPD is important, since it might shed light
on new trends in the development and course of the disease,
which in turn can lead to new insights and guidance for
prevention and treatment. Therefore, the objective of this
study is to investigate the prevalence and incidence of COPD
by age, sex and smoking status in the participants of the
Rotterdam Study, a large ongoing prospective population-
based cohort study with 25 years of follow-up.
Materials and methods
The present study was embedded within the Rotterdam
Study, an ongoing prospective population-based cohort
study that investigates the occurrence of chronic diseases and
risk factors in elderly. The objective and methods of this
cohort have been published previously [13, 14]. Briefly, the
Rotterdam Study (RS) includes approximately 15,000 par-
ticipants agedC45 years, living inOmmoord, awell-defined
suburb of the city of Rotterdam, the Netherlands, and
encompasses three cohorts: RS I, RS II and RS III. Baseline
data were collected between 1989 and 1992 in RS I (c 7983),
between 2000 and 2003 in RS II (n = 3011) and between
2006 and 2009 in RS III (n = 3932); thereafter cross-sec-
tional surveys and examinations have been conducted every
4–5 years. Participants were initially interviewed at home
for information on their health status. This was followed by
an extensive set of examinations performed at a specially
built research facility in the study district. Trained research
assistants collected information from medical records of the
general practitioners (GPs), nursing homes and hospitals.
The study was approved by the medical ethics committee of
Erasmus Medical Center, Rotterdam. All participants gave
their written informed consent and permission to retrieve
information from treating physicians.
COPD diagnosis
COPD was diagnosed based on an obstructive pre-bron-
chodilator spirometry (FEV1/FVC\ 0.70) according to the
GOLD guidelines [2, 15, 16]. We also diagnosed COPD
according to the lower level of normal (LLN) instead of
GOLD as a sensitivity analysis as proposed by Hankinson
et al. [17]. Spirometrywas performed by trained paramedical
personnel according to the ATS/ERS guidelines, using a
portable spirometer (SpiroPro; Erich Jaeger GmbH;
Hoechberg, Germany) from 2002 to 2008, and using a
Master Screen PFT Pro (Care Fusion, the Netherlands)
since 2009. Spirometry results which did not meet ATS/ERS
criteria for acceptability were classified as not inter-
pretable [18, 19]. Reversibility tests were not performed.
Within the Rotterdam study, pre-bronchodilator
spirometry was performed in 8411 participants. In 7188
subjects, the spirometry met ATS/ERS criteria and was
thus interpretable. In absence of an interpretable study-
acquired spirometry, the medical records including letters
from specialists and the electronic GP files were reviewed
of all patients who regularly used medication for obstruc-
tive lung disease (Anatomical Therapeutic Chemical
Classification codes: R03). Drug use was exclusively used
for potential case finding; each such potential case was
subsequently validated through careful evaluation of all
medical records, hospitalizations and specialist letters and
only included if a clear and well-founded diagnosis of
COPD was retained. Cases were then defined as having
physician diagnosed COPD based on clinical presentation
and obstructive lung function measured by the GP or res-
piratory physician.
The incident date was defined as the date of the first
obstructive lung function examination, the date of COPD
diagnosis in the medical records or the date of first pre-
scription of the COPD medication (in those with estab-
lished COPD), whichever came first.
Prevalent cases were defined as having COPD at
inclusion. Incident cases were defined as participants who
acquired COPD during follow-up. For incident COPD
cases, follow-up time was defined as the time period
between the start of the study and the diagnosis of COPD,
lost to follow up, death, or the last visit to the study centre
(December, 2014).
Statistical analysis
Statistical analysis was performed using SPSS statistical
software (SPSS for Windows, version 21; SPSS; Chicago,
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IL), R (Foundation for Statistical Computing, Vienna,
Austria) and Microsoft Excel (version 2010). For the sta-
tistical analyses, patients without informed consent for
follow-up were excluded. The prevalence of COPD (%)
was calculated by dividing the total number of COPD cases
at baseline (prevalent cases) by the total number of par-
ticipants included. The prevalence at the end of follow-up
(%) was calculated as the total number of COPD cases at
the end of this study divided by the total number of par-
ticipants included. For the analysis of the incidence rate of
COPD, patients with prevalent COPD at baseline were
excluded. Median follow up time was estimated using the
reverse Kaplan–Meier method (also called Kaplan–Meier
estimate of potential follow-up method). Incidence rates
were calculated by dividing the number of incident cases
by the total number of person years of subjects at risk and
are presented per 1000 person years. The 95 % Confidence
Intervals (CI) were calculated using a Poisson distribution.
Incidence rates were stratified for sex, age, and self-re-
ported smoking behaviour at baseline. To study age-
specific incidence rates, follow-up time was divided by
five-year age intervals as described before [18]. Subjects
contributed to the subsequent age intervals until they
developed COPD, were lost to follow up, died, or reached
the end of study (December, 2014). Smoking behaviour
was categorised as current, former and never.
Results
In this cohort of 14,619 participants with informed consent
for follow-up, a total of 1993 individuals (56.5 % males)
were identified as having COPD and 12,626 participants
(38.8 % males) did not have COPD. Physician diagnosed
asthma patients (n = 460) were excluded from the COPD
cases, but were controls, as they were at risk to develop
COPD. In addition, 54 asthma cases were added to the
COPD group since they developed COPD during follow-
up. A total of 311 of the 460 (68 %) asthma cases also
performed an interpretable (pre-bronchodilator) spirometry
within the Rotterdam Study of whom 60 had an obstructive
lung function examination (FEV1/FVC\ 0.7). A total of
689 COPD subjects were identified as having prevalent
COPD at baseline and 1304 COPD cases were incident
(Fig. 1). The median follow-up time was 10.7 years (with a
maximum follow-up time up to 25 years) and mean age at
baseline was 65.8 ± 10.4 years.
Regarding the smoking status, 21.7 % of the study
participants were current smokers, 41.7 % former smokers
and 34.2 % never smokers (Table 1). In ever smokers,
17.8 % (1663/9169) had COPD (including incident and
prevalent cases), whereas in never smokers the prevalence
of COPD was 6.4 % (318/4997). In men, 17.3 %
(n = 1042/6024) were never smokers, compared to 46.0 %
(n = 3955/8595) never smoking women. The proportion of
COPD female cases without a smoking history was 27.2 %
(236/867), while the proportion of never smokers among
COPD male cases was 7.3 % (82/1126). Amongst the
incident COPD patients who never smoked, questionnaire
information on passive smoking was available in 170
patients. The proportion of passive smoking in these
patients was 51.2 % (n = 87) and amongst these passive
smokers, the majority were female (n = 67; 77 %).
The prevalence of COPD at baseline in the Rotterdam
Study was 4.7 % (689/14,619) and the prevalence at the
end of follow-up was 13.6 % (1993/14,619). The overall
incidence rate (IR) of COPD was 8.9/1000 person-years
(PY) (95 % CI 8.4–9.4/1000 PY). For the sensitivity
analysis using LLN instead of the GOLD classification
method, the overall incidence rate was 5.5/1000 PY (95 %
CI 5.2–5.9) (See Table 2S in the online resource for
detailed information on the prevalence and incidence data
according to different classification methods; GOLD and
LLN).
Subgroup analysis of the spirometry data based on
GOLD (n = 7153) versus medical record data (n = 7466)
was also performed. The prevalence of COPD was 5.3
versus 4.2 %, respectively. The incidence rate of COPD
was 11.7/1000PY (95 % CI 10.9–12.4) versus 5.8/1000PY
(95 % CI 5.3–6.4), respectively (Table 2S). Additional
information is provided on severity and respiratory com-
plaints in the spirometry group in online Table 3S.
The overall IR was higher in men (13.3/1000 PY, 95 %
CI 12.4–14.3) than in women (6.1/1000 PY, 95 % CI
5.6–6.6); age specific IR ranged between 8.7 and 17.6/1000
PY in males and 3.0–7.9/1000 PY in females. The inci-
dence of COPD increased from the age of 45 in both sexes
to the age of 80 in men and 75 in women (Fig. 2). The IR
was higher in current and former smokers than in never
smokers (19.7/1000 PY, 95 % CI 18.1–21.4 in current
smokers, 8.3/1000 PY, 95 % CI 7.6–9.1 in former smokers
and 4.1/1000 PY, 95 % CI 3.6–4.7, in never smokers). The
IR of COPD in smoking men was 15.0/1000 PY (95 % CI
13.9–16.2) compared to 8.6/1000 PY (95 % CI 7.8–9.5) in
smoking women. The age-specific IR of COPD in ever
smokers ranged between 7.3 and 15.3/1000 PY. The IR
was 6.0/1000 PY (95 % CI 4.6–7.8) in never smoking men
and 3.7/1,000 PY (95 % CI 3.1–4.3) in never smoking
women. The age-specific incidence of COPD in never
smokers increased by age, but to a lesser extent than the
incidence of COPD in ever smokers (Fig. 3). After strati-
fication by sex and smoking history, the age-specific inci-
dence in never smoking women showed the same pattern
(Fig. 4).
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n= 14,926 Eligible subjects
n= 14,619 Included  
n= 689 prevalent cases 
n = 307 
Participants without consent for follow up 
were excluded 
n=  12,626 Participants without COPDn= 1,993 COPD cases
n= 1,304 incident cases 
Fig. 1 Flow chart of participants in the study
Table 1 Baseline
characteristics of the study







Age (years) at baseline 65.8 (10.4) 64.8 (8.5) 65.9 (10.6)
Gender n (%)
Males 6024 (41.2) 1126 (56.5) 4898 (38.8)
Females 8595 (58.8) 867 (43.5) 7728 (61.2)
Genetic ethnicity n (%)
Central European 11,617 (98.0) 1638 (98.9) 9979 (97.9)
Asian 145 (1.2) 14 (0.8) 131 (1.3)
African 69 (0.6) 2 (0.1) 67 (0.7)
Admixed 21 (0.2) 3 (0.2) 18 (0.2)
Missing genetic data n 2767 336 2431
Smoking at baseline n (%)
Current smoker 3078 (21.7) 800 (41.0) 2278 (18.6)
Former smoker 6091 (43.0) 831 (42.6) 5260 (43.1)
Never smoker 4997 (35.3) 318 (16.3) 4679 (38.3)
Missing n 453 44 409
Pack years of smoking mean (SD)
Current smoker 30.3 (21.3) 34.6 (19.8) 28.7 (21.5)
Former smoker 22.0 (23.8) 33.6 (28.5) 20.2 (22.5)
Missing n 770 77 693
Anthropometry mean (SD)
Weight (Kg) 76.0 (13.9) 76.2 (13.4) 76.0 (14.0)
Height (cm) 168.0 (9.6) 170.5 (9.4) 167.6 (9.5)
BMI 26.9 (4.1) 26.1 (3.9) 27.0 (4.1)
Missing n 1559 143 1416
Blood pressure mean (SD)
Systolic blood pressure (mmHg) 139.6 (36.3) 138.1 (32.4) 139.8 (36.9)
Diastolic blood pressure (mmHg) 78.5 (33.7) 77.7 (29.1) 78.6 (34.4)
Missing n 1392 131 1261
Data are presented as n (% of valid total) or Mean ± standard deviation (SD)
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Discussion
In this large prospective cohort study, the baseline preva-
lence of COPD was 4.7 % and the prevalence at the end of
follow-up was 13.6 %. The overall incidence rate of COPD
was approximately 9/1000 PY. This rate increased pro-
gressively with age, was higher in men than in women and
higher in ever smokers compared to never smokers.
Importantly, more than one in four female COPD subjects
was a never smoker.
We previously published on the prevalence and inci-
dence rates of COPD in the first Rotterdam Study (RS I;
encompassing 7983 participants) over a follow-up period
of 15.5 years (from 1989 till 2004) [18]. Here we report on
the prevalence and incidence rates of COPD in all three RS
cohorts (encompassing 14,926 participants) with an
extended follow-up period of up to 25 years (from baseline
till 2014). Comparing the results, the overall incidence rate
in both studies showed high consistency (IR: 9.2/1000 PY
[95 % CI; 8.5–10] in RS I versus 8.9/1000 PY [95 % CI;
8.4–9.4] in RS I, II and III combined). Given that both
cohort studies used overlapping but different data sources
(RS I versus RS I, II and III) and had different lengths of
follow-up (15.5 versus 25 years), the consistency found
highlights the reliability of the epidemiologic data.
Reviewing the literature, several studies reported on the
prevalence of COPD. These prevalences varied widely and
ranged from 0.2 % in Japan to 37 % in the USA and
between 2.1 and 26.1 % in Europe [7, 8]. Bischoff et al.
presented data on the prevalence of COPD in a dynamic
general practice population aged 40 and older in the
Netherlands using data from the Continuous Morbidity
Registration [20]. Their prevalence (5.4 %) was in line
with the one found in our study (4.7 %).
Numerous studies reported on the incidence of COPD but
only few studies reported the incidence rate in large cohorts
with long follow-up time taking the individual contribution
to follow-up into account (see supplementaryTable 1S). The
reported measures on the incidence varied widely when
reported in terms of rates per 1000 persons, ranging from 8.2
to 81.6 [21–23],while the incidence rates reported per person
time units ranged from 2.6 to 9.2 per 1000 PY [18, 24–27].
This variation in incidence rates can be explained by vari-
ability in terms of the definition of COPD, researchmethods,
source population and calendar time [7].
Overall, our study confirms that the incidence of COPD is
higher in men than in women and in elderly ([75y) than in
younger subjects. At our study centre, COPD was diagnosed
based on an obstructive (pre-bronchodilator) spirometry. If
Fig. 2 Age-specific incidence of COPD by sex
Fig. 3 Age specific incidence of COPD by smoking behaviour
Fig. 4 Age-specific incidence of COPD by sex (a men and b women)
and smoking behaviour
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an interpretable spirometry was not available, COPD was
defined as a validated diagnosis made by the GP or the res-
piratory physician on the basis of clinical presentation and
obstructive lung function. Therefore, not only symptomatic
but (in contrast to the patients seen by the physician in the
clinic) also asymptomatic or oligosymptomatic subjectswith
COPD were diagnosed in the RS. Since mild COPD cases
rarely seek medical attention, the true incidence of COPD is
frequently underestimated in clinical settings [23]. Studies
that reported on physician diagnosed COPD showed lower
IRs compared to the rate found in our epidemiologic study
[24, 25, 28] (Table 1S). In our study, subgroup analysis of the
spirometry data versus medical record data were also cal-
culated. The incidence rates showed a similar pattern as
compared to the literature and were 11.7/1000 PY using
spirometry data versus 5.8/1000 PY using medical records
data.
In this study, we classified COPD cases according to
GOLD guidelines. Since ATS and ERS recently advocate
the use of the Lower Limit of Normal (LLN), we also
recalculated the incidence rate using LLN classification in
the spirometry group instead of GOLD. The overall inci-
dence rate after reclassifying the spirometry based COPD
cases according to LLN was lower than the initial inci-
dence rate using GOLD (5.5/1000PY versus 8.9/1,000 PY)
which is in line with the literature [29]. This difference is
ascribed to the fact that mild COPD cases as classified
according to GOLD were considered as controls when LLN
was used as a cut-off. Whether mild (asymptomatic) COPD
should be classified as COPD is sometimes debated.
However, Mannino et al. [30] demonstrated that subjects
classified as ‘‘cases’’ using GOLD but as ‘‘normal’’ using
LLN have a significantly higher risk of COPD-related
hospitalization and mortality.
In our study, the age-specific incidence of COPD in
never smokers increased by age, but to a lesser extent than
the incidence of COPD in current and former smokers
(Fig. 3). The detection of COPD cases in never smokers
indicates that, besides tobacco smoking, other factors such
as genetic susceptibility, impaired lung growth, respiratory
infections and environmental exposures including occupa-
tional exposures and (outdoor and indoor) air pollution
might contribute to the development of COPD [10–12].
Interestingly, in our study, approximately 27.2 % of all
female COPD cases were never smokers, whereas this
prevalence was much lower in men (7.3 %). This suggests
that the contribution of environmental exposures other than
active smoking leading to COPD seems more substantial in
females than in males. Indeed, our data confirm that one of
these environmental exposures, namely passive smoking, is
higher in females than in males [31–33].
Likewise, more evidence is emerging on the increasing
occurrence of COPD in non-smoking individuals,
especially in females. Worldwide an estimated 25–45 % of
patients with COPD never smoked [10]. Nevertheless, most
randomized clinical trials (RCT) that examine the efficacy
and safety of pharmacologic treatments for COPD, only
include COPD patients with a history of cigarette smoking
of at least 10 pack years [10].
The burden of COPD in never smokers is higher than
previously believed [10, 11, 31, 34], therefore more
research is needed to unravel the characteristics of non-
smoking COPD in order to address the true burden, prog-
nosis, clinical, radiographic and physiological features and
treatment possibilities in this specific and neglected group.
The strengths of the Rotterdam study are the prospec-
tive, population-based design with a follow-up time of
25 years. In addition, measurements of the variables in this
prospective cohort is done independently of the research
question, which makes it less prone to information and
selection bias.
A limitation is that spirometry measurements were
introduced in the Rotterdam study in January 2002 and
therefore measured in only 8411 participants (out of 9950
still alive). This could lead to an underestimation of
asymptomatic COPD in the Rotterdam Study in partici-
pants without spirometry. A second limitation is that within
the Rotterdam Study, as in most population-based cohort
studies, reversibility tests were not performed, because the
use of inhaled bronchodilators could interfere with other
tests during the study visit. This could inflate the preva-
lence of COPD considerably [35, 36]. While some
researchers state that the use of a bronchodilator is neces-
sary to eliminate the variable airflow limitation in order to
diagnose COPD [37], others suggest that bronchodilator
responsiveness is anyway greatly variable and that more
than 50 % of the patients who initially were classified as
reversible would be reclassified, had they attended on a
different occasion [38, 39]. The use of pre-bronchodilator
spirometry implies that we cannot exclude the possibility
of misclassification of some asthma patients as COPD
patients. To minimize the risk of misclassification, we
additionally identified and validated patients with physi-
cian-diagnosed asthma. However, we still acknowledge the
use of pre-bronchodilatory test results as weakness because
some unknown degree of inflation of COPD diagnoses
might still be present.
In conclusion, the overall incidence rate of COPD in the
Rotterdam Study was approximately 9/1000 PY, with a
higher incidence in males and in smokers. The proportion
of never smokers among COPD cases is substantial and
higher in females than in males.
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